Abstract： The prevalence of multidrug/rifampicin-resistant tuberculosis is still a major problem in China and around the world. Bedaquiline is one of the key drugs in the treatment of multidrug/rifampicin-resistant tuberculosis, with the potential to improve outcomes and reduce mortality. Bedaquiline has a promising future in oral short-course treatment regimens, in combination with other novel anti-tuberculosis drugs, and in a special patient population. In this feature article, we discussed the current status and future prospects of the clinical application of bedaquiline in order to provide references for physicians.